Mesenchymal stem cells may eventually be able to grow and strengthen muscles in humans, according to researchers at the University of Illinois. In mice, an injection of such stem cells helped rejuvenate skeletal muscle after exercise.
Scientists at Washington University in St. Louis have discovered one method by which malaria parasites resist drugs.
The National Institutes of Health is launching three new programs in emerging areas with the lofty goal of transforming biomedical research in the next 5 to 10 years.
For William Strohl, the new head of Janssen's Biotechnology Center of Excellence, the future of drug R&D involves novel targets, "fit-for-purpose" antibodies and lots of collaborations.
An experimental anti-inflammatory drug delivered via a shot in the skin prevents neuron loss in rats with Parkinson's disease, according to a new study by researchers from Emory University School of Medicine in Atlanta.
In response to back-to-back incidents involving government laboratories, a top official at the U.S. Centers for Disease Control and Prevention has resigned, and the agency has assembled a safety board to address concerns that have arisen after workers were potentially exposed to anthrax and H5N1 flu.
Researchers at the University of Iowa have developed a vaccine that showed protection in mice against dust mite allergies.
Startup Neurotrope is teaming up with the Icahn School of Medicine at Mount Sinai in New York City to further develop its bryostatins for the treatment of Niemann-Pick disease type C, a rare disease that mostly affects children.
In 2008, the U.S. National Institutes of Health began releasing to the public how much the agency spends in various research categories. I decided to pick out the top-funded disease areas to get a sense of what disorders and diseases the U.S. government is prioritizing.
A new discovery of an ancestral fossil virus buried within everyone's genomes might provide the key to eradicating HIV.
An in vitro technique using samples of beating heart tissue may be able to test the effects of drugs on the heart without unnecessary testing on humans or animals, according to new research.
The U.S. Centers for Disease Control and Prevention reports that the first locally acquired case of chikungunya, a mosquito-borne virus that causes symptoms similar to those of dengue fever, has surfaced in the U.S. in Florida.
Much of Alzheimer's drug research has focused on targeting amyloid beta, a protein long thought to be toxic when it clumps together to form plaques in the brain.
Injecting a gene directly into the heart may be able to replace the need for an electronic pacemaker, according to new research by scientists at the Cedars-Sinai Heart Institute.
A protein found to be essential to the survival of Escherichia coli bacteria may provide a new target for antibiotics, according to researchers from Ohio State University.
Drug development in the Alzheimer's field has been riddled with failures, and many research efforts have focused on pinpointing genetic and environmental factors responsible for causing or accelerating the progression of the disease.
Investigators at the University of Wisconsin-Madison have figured out a way to genetically program stem cells into both red and white cells that make up human blood.
A chemical compound designed by researchers at the University of California, San Francisco, protected mice and rats against degenerative forms of blindness and diabetes by targeting a central stress response area.
Scientists at drug giant Eli Lilly have found that a combination therapy may be more effective at removing clumps of amyloid-β protein--widely thought to contribute to the development of Alzheimer's disease--than the use of one therapy in mice.
Biodefense company Soligenix revealed new data showing that a combination of its vaccines RiVax and VeloThrax induced protective immunity to both ricin toxin and anthrax toxin exposure in an animal study.